A VLP for validation of the Plasmodium falciparum circumsporozoite protein junctional epitope for vaccine development.

ABSTRACT: Malaria continues to be a pressing global health issue, causing nearly half a million deaths per year. An effective malaria vaccine could radically improve our ability to control and eliminate this pathogen. The most advanced malaria vaccine, RTS,S, confers only 30% protective efficacy under field conditions, and hence the search continues for improved vaccines. New antigens and formulations are always first developed at a pre-clinical level. This paper describes the development of a platform to supplement existing tools of pre-clinical malaria vaccine development, by displaying linear peptides on a virus-like particle (VLP). Peptides from PfCSP, particularly from outside the normal target of neutralizing antibodies, the central NANP repeat region, are screened for evidence of protective e

SUBMITTER: Atcheson E 

PROVIDER: S-EPMC8016880 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature